This study, called LIVELONG, is looking at how well adding local ablative therapies (treatments that destroy cancer cells in a specific area) works for certain gastrointestinal cancers that have started to grow again in a limited way, even while you're on other treatments. It's for people with small bowel, colorectal, appendiceal, biliary, or gallbladder cancers. The study will use either Stereotactic Ablative Radiotherapy (SABR) or interventional radiology (IR) ablation therapy. The main goal is to see if your disease is controlled three months after starting these local treatments. The study is currently unclear on its recruitment status and plans to enroll 300 participants.

Study design

This is a phase 2 study involving 300 participants at a single site. It is designed to evaluate the clinical benefit of adding local ablative therapies to ongoing systemic therapy.

What's involved

Participants will receive ablative local therapy in addition to their current systemic therapy. They will be followed for up to 5 years after the ablative local therapy.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 5 years after receiving ablative local therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.